Showing results (31-40 of 116) with videos related to
Sort By:
Pageof 12
Pain and Therapy|May 7, 2022
Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled TrialLynn R Webster, Jacqueline Cater, Thomas SmithSubstance Abuse and Rehabilitation|July 2, 2016
Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individualsLynn R Webster, Michael Camilleri, Andrew FinnExpert Opinion on Investigational Drugs|February 27, 2009
Opioid formulations in development designed to curtail abuse: who is the target?Lynn R Webster, Brad Bath, Robert A MedvePostgraduate Medicine|December 20, 2014
Eight principles for safer opioid prescribing and cautions with benzodiazepinesLynn R Webster, Gary M Reisfield, Nabarun DasguptaCurrent Medical Research and Opinion|December 24, 2015
Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trialsBeatrice Setnik, Glenn C Pixton, Lynn R WebsterHandbook of Clinical Neurology|January 15, 2013
Neuropathic painEric Kerstman, Sangmin Ahn, Sree Battu, et al.Journal of Opioid Management|October 1, 2011
Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough painLynn R Webster, John Messina, Fang Xie, et al.Pain Medicine (Malden, Mass.)|April 4, 2017
A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer PainLynn R Webster, Tadaaki Yamada, Juan Camilo Arjona FerreiraAdvances in Therapy|September 26, 2020
A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory DriveLynn R Webster, Erik Hansen, Jacqueline Cater, et al.Postgraduate Medicine|December 6, 2016
Current and future development of extended-release, abuse-deterrent opioid formulations in the United StatesLynn R Webster, John Markman, Edward J Cone, et al.Pageof 12